First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors December 11, 2023
FDA granted “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic EDV (EnGeneIC Dream Vector) December 11, 2023
2nd Independent Safety Review of the ASPIRE Registration Clinical Trial Announced: Recommended Continuation with no Trial Modification December 4, 2023
Interim Results from Ph 2 Trial of IT LSAM-PTX in Locally Advanced Pancreatic Cancer Patients Announced October 16, 2023
Ph 1/2 Study of Azeliragon in Patients Refractory to 1L Treatment of Metastatic Pancreatic Cancer initiated October 3, 2023
Positive Clinical Data in Pancreatic Cancer and SCLC, including Single-Agent Activity from Onvansertib Monotherapy October 3, 2023
Positive outcome of the prespecified interim futility analysis for Ph 2b ASCEND trial of LSTA1 + SOC in patients with 1L mPDAC announced September 13, 2023
Favorable IDMC Recommendation to Continue Ph 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer July 27, 2023
New Positive Interim Ph 3 Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer Announced July 12, 2023
Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1st Line Pancreatic Cancer Announced July 5, 2023
RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer July 5, 2023
Zenocutuzumab granted Breakthrough Therapy Designation by US FDA for the treatment of NRG1+ pancreatic cancer July 5, 2023
FDA accepts Supplemental NDA for Onivyde regimen in 1L metastatic pancreatic ductal adenocarcinoma June 21, 2023
Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 31, 2023
Ph 3 interim data analysis of RenovoGem therapy for pancreatic cancer patients to be announced April 6, 2023
